China’s ambition to dominate the emerging field of brain-computer interfaces is rapidly taking shape, with one Shanghai-based start-up already reporting early human trials just a few years after its founding. NeuroXess, which develops brain implants that allow people to communicate directly with computers, recently announced that a paralyzed patient was able to control a computer cursor within five days of receiving the device. The achievement marks a significant milestone in China’s broader push to accelerate neurotechnology and challenge US firms such as Neuralink.
Tiger Tao, founder of NeuroXess, which was established in 2021, told the Financial Times that government support and investor enthusiasm allowed his team to drastically shorten the timeline from laboratory development to human application. “This is the most important benefit from the government support,” Tao said. “For us, time is equal to money.” The company’s implant consists of a polyimide and metal mesh that sits on the brain’s surface, capturing neural signals and relaying them via a chest-mounted processor to external computers, a system currently focused on patients with severe physical disabilities such as paralysis or amyotrophic lateral sclerosis (ALS).
The acceleration of BCI development in China is part of an explicit national strategy. Last year, Beijing designated the technology a strategically important sector and published a roadmap aiming to create two to three “world-class” companies by 2030. The plan includes streamlined regulations, encouragement of clinical trials, and substantial capital mobilization, signaling long-term political support. Since February 2025, at least ten clinical trials for invasive brain implants have been launched, and financing activity in the sector is surging: in the first eleven months of 2025 alone, 24 BCI start-ups closed financing rounds, a 30 percent increase from the previous year, according to Dongmaicheng data.
“Chinese companies are moving very aggressively to get these devices into patients and find more applications,” said Max Riesenhuber, a neuroscientist at Georgetown University who studies brain-computer interfaces. Tao emphasized that China’s large patient population makes recruitment for trials easier, noting that millions of patients suffer from total motor and language loss, often due to accidents, and are willing to participate in cutting-edge therapies.
While US and European firms, including Neuralink, Merge Labs, and other emerging players, are also developing BCIs, NeuroXess has taken a distinct technical approach. Early animal testing with electrodes inserted directly into the brain caused scarring that degraded signal quality over time. Instead, NeuroXess implants a flexible metal mesh atop the brain, capturing signals across a wide area without penetrating tissue. Neuralink, by contrast, relies on microscopic threads inserted into the brain that aim to minimize scarring, and its devices have reportedly achieved neural decoding speeds of up to ten bits per second, compared with the 5.2 bits per second reported by NeuroXess. Faster speeds are necessary for complex applications, including translating thoughts into speech.
Beyond invasive implants, Chinese companies are increasingly exploring non-invasive BCIs that sit outside the skull. Historically, these devices have struggled to capture precise signals, as neural activity weakens when passing through bone. Developers hope that combining methods such as ultrasound and magnetic imaging with advanced AI could dramatically enhance signal fidelity and broaden applications beyond medical use. Riesenhuber observed that advances in invasive devices improve understanding of the brain, potentially paving the way for non-invasive systems in the future.
Tao foresees a horizon where brain implants are miniaturized and the required surgery involves only a tiny incision. He argued that China’s industry is uniquely positioned to optimize devices quickly due to rapid data collection, cost reduction, and a growing user base. The country’s approach contrasts with Western firms, which often move more cautiously, citing regulatory hurdles and smaller patient populations for trials.
The broader implications of China’s BCI push are significant. By combining government support, a vast patient base, and substantial investment, the country is accelerating technological development at a pace that rivals Western innovation hubs. While Neuralink focuses on seamless brain-to-computer interfaces for broader human enhancement, NeuroXess is initially targeting urgent medical needs, aiming to restore communication and mobility for those most severely affected by neurological conditions.
The emerging competition underscores a global race to harness the transformative potential of BCIs, with applications ranging from medical rehabilitation to cognitive augmentation. China’s strategic focus on creating “world-class” BCI companies demonstrates the government’s commitment to becoming a dominant player in a field widely considered critical for the next frontier of human-computer interaction. As these developments unfold, the world will be watching closely to see whether Beijing’s investments and regulatory advantages translate into leadership in a technology that could redefine the interface between human minds and machines.
With early human successes like the NeuroXess implant and rapid clinical expansion, China is staking a claim in an arena long dominated by US innovators. Analysts note that the coming years will be pivotal, not only for the companies involved but for shaping global standards, regulations, and ethical frameworks surrounding brain-computer interfaces. As Tao concluded, the combination of policy, capital, and patient access gives China a unique advantage in moving from experimental devices to real-world impact, potentially rivaling the ambitions of Elon Musk and his contemporaries in the West.
